Andrew Davis’ Post

View profile for Andrew Davis

Investment Banking Senior Analyst at Back Bay Life Science Advisors

Deal making within healthcare in the first half of 2024 saw an increase in activity relative to 2023, espicially within IPOs, venture, and PIPEs/RDOs; however, the performance of healthcare equties has lagged behind the overall market as risk-aversion remains pervasive. For a full breakdown of the performance of healthcare equities and deal making across IPOs, Follow-Ons, PIPEs/RDOs, M&A, Licensing, and Venture see the full H1 report below that I assembled alongside my investment banking colleagues at Back Bay Life Science Advisors. US & EU Healthcare 2024 H1 Review 👉 https://lnkd.in/epJXC9Ng

To view or add a comment, sign in

Explore topics